title: A preliminary assessment of macular function by MF-ERG in myopic eyes with CNV with complete response to photodynamic therapy.
abstract: OBJECTIVE
  To evaluate by multifocal electroretinogram (MF-ERG) macular function before and after photodynamic therapy (PDT) in myopic eyes with choroidal neovascularization (CNV).
  
  
  METHODS
  Ten eyes with classic subfoveal CNV due to pathologic myopia were studied with MF-ERG before and after PDT in order to evaluate the results of PDT with verteporfin. The post-treatment follow-up was 6 months. Visual acuity testing, ophthalmic examinations, fluorescein and indocyanine green angiograms, and MF-ERG recordings were used to evaluate the results of PDT with verteporfin. The post-treatment period was 6 months.
  
  
  RESULTS
  Before treatment, the electrical response densities in the foveal and perifoveal areas were apparently decreased in all patients. Six months after treatment, the mean retinal response densities in the same areas were found to be higher than before treatment.
  
  
  CONCLUSIONS
  MF-ERG evaluates objectively the macular function in myopic eyes with CNV. After successful PDT, the electrical activity of the foveal and parafoveal areas is higher than before treatment. This finding postulates the efficacy of PDT in the treatment of CNV.
authors.affiliation: Eye Department, Athens University, Athens, Greece. Mosxos@hellasnet.gr
authors.forename: M N
authors.initials: MN
authors.lastname: Moschos
authors.forename: D
authors.initials: D
authors.lastname: Panayotidis
authors.forename: M M
authors.initials: MM
authors.lastname: Moschos
authors.forename: Chr
authors.initials: C
authors.lastname: Bouros
authors.forename: P G
authors.initials: PG
authors.lastname: Theodossiadis
authors.forename: G P
authors.initials: GP
authors.lastname: Theodossiadis
mesh_terms: D000328:Adult; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D004396:Coloring Agents; D004596:Electroretinography; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007208:Indocyanine Green; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000150:complications*; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D011379:Prognosis; D012160:Retina / Q000502:physiology*; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D004396:Coloring Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D007208:Indocyanine Green